5-FU and its biomodulator leucovorin are used for the treatment of various solid tumours. Credit: National Cancer Institute on Unsplash.

FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol in markets across the globe.

Under the partnership, Treehill will support FivepHusion with operational, strategic and transactional expertise along with integrated business development.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Syneos will support the commercialisation and clinical development capabilities of FivepHusion.

FivepHusion CEO and managing director Dr Christian Toouli said: “By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol to global markets, including in the US, Europe and Asia.

“Through the combined strength and competency of three industry leaders, we intend to maximise our progress on the development of Deflexifol and quickly bring innovative oncology medicines to patients in need.”

Deflexifol is a new and optimised physiological pH formulation developed for the co-administration of the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

These drugs are used for the treatment of various solid tumours including gastric, pancreatic, colorectal and breast cancers.

Treehill partner and co-founder Ali Pashazadeh said: “By merging the scientific prowess of our clients with the clinical and commercial expertise of Syneos Health and Treehill’s healthcare advisory and execution capabilities, we are providing a unique ecosystem designed to help companies to flourish despite the current challenging market environment.”

Deflexifol is also being developed to treat paediatric ependymoma, a rare and deadly brain cancer affecting very young children.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact